Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Improving the Care of Individuals with Schizophrenia and Substance Use Disorders: Consensus Recommendations

Open access
ZIEDONIS, DOUGLAS M., SMELSON, DAVID, ROSENTHAL, RICHARD N., BATKI, STEVEN L., GREEN, ALAN I., HENRY, RENATA J., MONTOYA, IVAN, PARKS, JOSEPH, WEISS, ROGER D.·2005·Journal of Psychiatric Practice

Abstract

National attention continues to focus on the need to improve care for individuals with co-occurring mental illnesses and substance use disorders, as emphasized in the 2003 President's New Freedom Commission Report on Mental Health and recent publications from the Substance Abuse and Mental Health Services Administration (SAMHSA). These reports document the need for best practice recommendations that can be translated into routine clinical care. Although efforts are underway to synthesize literature in this area, few focused recommendations are available that include expert opinion and evidence-based findings on the management of specific co-occurring disorders, such as schizophrenia and addiction. In response to the need for user-friendly recommendations on the treatment of schizophrenia and addiction, a consensus conference of experts from academic institutions and state mental health systems was organized to 1) frame the problem from clinical and systems-level perspectives; 2) identify effective and problematic psychosocial, pharmacological, and systems practices; and 3) develop a summary publication with recommendations for improving current practice. The results of the consensus meeting served as the foundation for this publication, which presents a broad set of recommendations for clinicians who treat individuals with schizophrenia. "Integrated treatment" is the new standard for evidence-based treatment for this population and recommendations are given to help clinicians implement such integrated treatment. Specific recommendations are provided concerning screening for substance use disorders in patients with schizophrenia, assessing motivation for change, managing medical conditions that commonly occur in patients with dual diagnoses (e.g., cardiovascular disease, liver complications, lung cancer, HIV, and hepatitis B or C infections) and selecting the most appropriate medications for such patients to maximize safety and minimize drug interactions, use of evidence-based psychosocial interventions for patients with dual diagnoses (e.g., Dual Recovery Therapy, modified cognitive-behavioral therapy, modified motivational enhancement therapy, and the Substance Abuse Management Module), and key pharmacotherapy principles for treating schizophrenia, substance use disorders, and comorbid anxiety, depression, and sleep problems in this population. Finally the article reviews programmatic and systemic changes needed to overcome treatment barriers and promote the best outcomes for this patient population. An algorithm summarizing the consensus recommendations is provided in an appendix.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00131746-200509000-00005

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 99

  1. Regier, 1990, JAMA, 264, 2511, 10.1001/jama.1990.03450190043026 · DOI · Paper page
  2. de Leon, 1996, Schizophr Bull, 22, 405, 10.1093/schbul/22.3.405 · DOI
  3. Ziedonis, 2004, CNS Spectrums, 9, 892, 10.1017/S1092852900009718 · DOI
  4. Sacks, 1997, Subst Use Misuse, 32, 1217, 10.3109/10826089709035472 · DOI
  5. Caton, 1994, Am J Pub Health, 84, 265, 10.2105/AJPH.84.2.265 · DOI · Paper page
  6. Cuffel, 1994, J Nerv Ment Disease, 182, 704, 10.1097/00005053-199412000-00005 · DOI
  7. Haywood, 1995, Am J Psychiatry, 152, 856, 10.1176/ajp.152.6.856 · DOI · Paper page
  8. Serper, 1995, Am J Psychiatry, 152, 1464, 10.1176/ajp.152.10.1464 · DOI
  9. Smelson, 2002, J Nerv Ment Dis, 190, 200, 10.1097/00005053-200203000-00010 · DOI
  10. Drake, 2001, Psychiatr Serv, 52, 469, 10.1176/appi.ps.52.4.469 · DOI · Paper page
  11. Bellack, 1999, Psychiatr Serv, 50, 75, 10.1176/ps.50.1.75 · DOI
  12. Carey, 1997, Psychol Addict Behav, 11, 26, 10.1037/0893-164X.11.1.26 · DOI · Paper page
  13. Rosenthal, 1992, Am J Addict, 1, 339
  14. Shaner, 2003, Psychiatr Serv, 54, 1287, 10.1176/appi.ps.54.9.1287 · DOI
  15. Ziedonis, 1994, Hosp Community Psychiatry, 45, 204
  16. Teitelbaum, 1997, The Behavior Therapist, 20, 19
  17. Skinner, 1982, J Stud Alcohol, 43, 1157, 10.15288/jsa.1982.43.1157 · DOI · Paper page
  18. Rosenberg, 1998, Am J Psychiatry, 155, 232, 10.1176/ajp.155.2.232 · DOI · Paper page
  19. Carey, 1998, Addict Behav, 23, 735, 10.1016/S0306-4603(98)00063-X · DOI
  20. Bartels, 1993, J Nerv Ment Dis, 181, 227, 10.1097/00005053-199304000-00003 · DOI · Paper page
  21. Mueser, 1992, J Consult Clin Psychol, 60, 845, 10.1037/0022-006X.60.6.845 · DOI · Paper page
  22. Ziedonis, 1996, Dir Psychiatry, 16, 1
  23. Allen, 2001, J Subst Abuse Treat, 20, 81, 10.1016/S0740-5472(00)00144-6 · DOI
  24. Ziedonis, 1997, Schizophr Bull, 23, 229, 10.1093/schbul/23.2.229 · DOI · Paper page
  25. Ries, 1990, Hosp Community Psychiatry, 41, 1230
  26. Mukamal, 2004, Am J Geriatr Cardiol, 13, 22, 10.1111/j.1076-7460.2004.01334.x · DOI
  27. Dalton, 2004, Am J Psychiatry, 161, 903, 10.1176/appi.ajp.161.5.903 · DOI
  28. Davidson, 2001, Aust N Z J Psychiatry, 35, 196, 10.1046/j.1440-1614.2001.00877.x · DOI · Paper page
  29. Allison, 1999, J Clin Psychiatry, 60, 215, 10.4088/JCP.v60n0402 · DOI · Paper page
  30. Dixon, 1999, J Nerv Ment Dis, 187, 496, 10.1097/00005053-199908000-00006 · DOI · Paper page
  31. Herran, 2000, Schizophr Res, 41, 373, 10.1016/S0920-9964(99)00082-1 · DOI
  32. McElroy, 2004, J Clin Psychiatry, 65, 634, 10.4088/JCP.v65n0507 · DOI · Paper page
  33. Marder, 2004, Am J Psychiatry, 161, 1334, 10.1176/appi.ajp.161.8.1334 · DOI · Paper page
  34. McCance, 1995, Pharmacol Exp Ther, 274, 215
  35. McCance-Katz, 1998, Biol Psychiatry, 44, 250, 10.1016/S0006-3223(97)00426-5 · DOI · Paper page
  36. Flegal, 1985, Recent Dev Alcohol, 3, 165, 10.1007/978-1-4615-7715-7_13 · DOI
  37. Kuo, 2004, Drug Alcohol Depend, 73, 69, 10.1016/j.drugalcdep.2003.10.007 · DOI
  38. Kellerman, 2003, J Infect Dis, 188, 571, 10.1086/377135 · DOI · Paper page
  39. Butterfield, 2003, Psychiatr Serv, 54, 848, 10.1176/appi.ps.54.6.848 · DOI
  40. Stoskopf, 2001, Community Ment Health J, 37, 469, 10.1023/A:1017577827658 · DOI
  41. Fernandez, 1991, Psychiatr Med, 9, 377
  42. Batki, 1990, West J Med, 152, 547
  43. Bagchi, 2004, Schizophr Res, 71, 435, 10.1016/j.schres.2004.02.021 · DOI
  44. Ziedonis, 2001, Psychiatr Ann, 31, 255, 10.3928/0048-5713-20010401-09 · DOI
  45. Carey, 1996, Community Ment Health J, 32, 291, 10.1007/BF02249430 · DOI · Paper page
  46. Bartels, 1996, J Nerv Ment Dis, 184, 379, 10.1097/00005053-199606000-00011 · DOI
  47. Blankertz, 1993, J Ment Health Adm, 20, 100, 10.1007/BF02519235 · doi:10.1007/bf02519235
  48. Hanson, 1990, J Subst Abuse Treat, 7, 109, 10.1016/0740-5472(90)90006-C · doi:10.1016/0740-5472(90)90006-c
  49. Hellerstein, 1995, Am J Addict, 4, 33, 10.1111/j.1521-0391.1995.tb00256.x · doi:10.1111/j.1521-0391.1995.tb00256.x
  50. Rahav, 1995, J Psychoactive Drugs, 27, 93, 10.1080/02791072.1995.10471677 · DOI
  51. Burnam, 1995, J Addict Dis, 14, 111, 10.1300/J069v14n04_07 · DOI
  52. Bennett, 2001, J Subst Abuse Treat, 20, 163, 10.1016/S0740-5472(00)00167-7 · DOI
  53. Mueser, 1998, Schizophr Bull, 24, 37, 10.1093/oxfordjournals.schbul.a033314 · DOI · Paper page
  54. Johnson, 1999, J Psychiatr Ment Health Nurs, 6, 445, 10.1046/j.1365-2850.1999.00252.x · doi:10.1046/j.1365-2850.1999.00252.x
  55. Schaedle, 2002, Psychiatr Serv, 53, 207, 10.1176/appi.ps.53.2.207 · DOI
  56. Rosenheck, 2001, Arch Gen Psychiatry, 58, 1073, 10.1001/archpsyc.58.11.1073 · DOI
  57. Okin, 2000, Am J Emerg Med, 18, 603, 10.1053/ajem.2000.9292 · DOI · Paper page
  58. Witbeck, 2000, J Subst Abuse Treat, 9, 39, 10.1016/S0740-5472(99)00090-2 · DOI
  59. Smelson, 2005, Journal of Dual Diagnosis, 1, 47, 10.1300/J374v01n03_05 · DOI
  60. Weiss, 1998, J Clin Psychiatry, 59, 172, 10.4088/JCP.v59n0405 · DOI
  61. Rychtarik, 2000, J Stud Alcohol, 61, 134, 10.15288/jsa.2000.61.134 · DOI
  62. Farren, 2000, Drug Alcohol Depend, 59, 153, 10.1016/S0376-8716(99)00114-3 · DOI
  63. Zevin, 1999, Clin Pharmacokinet, 36, 425, 10.2165/00003088-199936060-00004 · DOI · Paper page
  64. Desai, 2001, CNS Drugs, 15, 469, 10.2165/00023210-200115060-00005 · DOI · Paper page
  65. Bozikas, 2004, Eur Neuropsychopharmacol, 14, 39, 10.1016/S0924-977X(03)00061-0 · DOI
  66. McEvoy, 1999, J Clin Psychiatry, 60, 1
  67. Kane, 2003, J Clin Psychiatry, 64, 1
  68. Miller, 2004, J Clin Psychiatry, 65, 500, 10.4088/JCP.v65n0408 · DOI · Paper page
  69. Albanese, 1994, Am J Psychiatry, 151, 780
  70. Marcus, 1995, Am J Psychiatry, 152, 959
  71. Buckley, 1998, J Subst Abuse Treat, 15, 113, 10.1016/S0740-5472(97)00134-7 · DOI
  72. Tsuang, 1999, Am J Psychiatry, 156, 1119, 10.1176/ajp.156.7.1119a · DOI
  73. Tsuang, 2002, J Clin Psychopharmacol, 22, 629, 10.1097/00004714-200212000-00017 · DOI
  74. Buckley, 1994, Am J Psychiatry, 151, 385, 10.1176/ajp.151.3.385 · DOI
  75. Conley, 1998, Schizophr Res, 33, 95, 10.1016/S0920-9964(98)00062-0 · DOI
  76. Lee, 1998, Can J Psychiatry, 43, 855, 10.1177/070674379804300705 · DOI
  77. Drake, 2000, Schizophr Bull, 26, 441, 10.1093/oxfordjournals.schbul.a033464 · DOI · Paper page
  78. Zimmet, 2000, J Clin Psychopharmacol, 20, 94, 10.1097/00004714-200002000-00016 · DOI · Paper page
  79. Littrell, 2001, J Subst Abuse Treat, 21, 217, 10.1016/S0740-5472(01)00205-7 · DOI
  80. Smelson, 2002, Can J Psychiatry, 47, 671, 10.1177/070674370204700710 · DOI
  81. Poling, 2005, Addictive Disorders Their Treatment, 4, 1, 10.1097/00132576-200503000-00001 · DOI
  82. Levin, 1998, Am J Drug Alcohol Abuse, 24, 343, 10.3109/00952999809016902 · DOI
  83. Green, 2003, Schizophr Res, 60, 81, 10.1016/S0920-9964(02)00231-1 · DOI
  84. Smelson, 2003, Schizophr Res, 60, 303, 10.1016/S0920-9964(03)80226-8 · doi:10.1016/s0920-9964(03)80226-8
  85. Carol, 2001, Psychiatr Serv, 52, 1029, 10.1176/appi.ps.52.8.1029 · doi:10.1176/appi.ps.52.8.1029
  86. Smelson, 2002, Psychiatr Serv, 53, 1612, 10.1176/appi.ps.53.12.1612 · DOI
  87. George, 2000, Am J Psychiatry, 157, 1835, 10.1176/appi.ajp.157.11.1835 · DOI · Paper page
  88. Petrakis, 2004, Psychopharmacology (Berl), 172, 291, 10.1007/s00213-003-1658-9 · DOI
  89. Farren, 2002, Am J Addict, 11, 228, 10.1080/10550490290088009 · DOI
  90. Zimmet, 2000, J Clin Psychopharmacol, 20, 94, 10.1097/00004714-200002000-00016 · DOI · Paper page
  91. George, 2002, Biol Psychiatry, 52, 53, 10.1016/S0006-3223(02)01339-2 · DOI · Paper page
  92. Weiner, 2001, Am J Psychiatry, 158, 635, 10.1176/appi.ajp.158.4.635 · DOI
  93. Ziedonis, 1997, Schizophr Bull, 23, 247, 10.1093/schbul/23.2.247 · DOI · Paper page
  94. Williams, 2004, Addict Behav, 29, 1067, 10.1016/j.addbeh.2004.03.009 · DOI · Paper page
  95. Williams, 2004, Psychiatr Serv, 55, 1064, 10.1176/appi.ps.55.9.1064 · DOI
  96. DeQuardo, 1994, Psychiatr Res, 28, 267, 10.1016/0022-3956(94)90010-8 · DOI
  97. Negrete, 1986, Psychol Med, 16, 515, 10.1017/S0033291700010278 · DOI · Paper page
  98. Raphael, 2005, J Psychiatr Pract, 11, 161, 10.1097/00131746-200505000-00004 · DOI
  99. Ries, 1993, J Addict Dis, 12, 103, 10.1300/J069v12n03_09 · DOI

Cited by

See all 195

Metadata

Authors
ZIEDONIS, D. M., SMELSON, D., ROSENTHAL, R. N., BATKI, S. L., GREEN, A. I., HENRY, R. J., MONTOYA, I., PARKS, J., & WEISS, R. D.
Venue
Journal of Psychiatric Practice
Published
2005-09
Volume
11
Issue
5
Pages
315-339
ISSN
  • 1527-4160 (ISSN-L)
  • 1538-1145
OpenAlex
W1971540569
Cited by
195
References
9
FWCI
7.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improving the Care of Individuals with Schizophrenia and Substance Use Disorders: Consensus Recommendations. https://app.cochat.ai/papers/10.1097/00131746-200509000-00005
The paper
ZIEDONIS, D. M., SMELSON, D., ROSENTHAL, R. N., BATKI, S. L., GREEN, A. I., HENRY, R. J., MONTOYA, I., PARKS, J., & WEISS, R. D. (2005). Improving the Care of Individuals with Schizophrenia and Substance Use Disorders: Consensus Recommendations. Journal of Psychiatric Practice. https://doi.org/10.1097/00131746-200509000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.